INDIVIOR PHARMACEUTICALS INC (INDV) Fundamental Analysis & Valuation
NASDAQ:INDV • US45579U1097
Current stock price
30.42 USD
-0.05 (-0.16%)
At close:
30.42 USD
0 (0%)
After Hours:
This INDV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. INDV Profitability Analysis
1.1 Basic Checks
- In the past year INDV was profitable.
- In the past year INDV had a positive cash flow from operations.
- In multiple years INDV reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: INDV reported negative operating cash flow in multiple years.
1.2 Ratios
- INDV has a Return On Assets of 8.62%. This is amongst the best in the industry. INDV outperforms 89.58% of its industry peers.
- With an excellent Return On Invested Capital value of 50.62%, INDV belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- INDV had an Average Return On Invested Capital over the past 3 years of 43.06%. This is significantly above the industry average of 13.06%.
- The last Return On Invested Capital (50.62%) for INDV is above the 3 year average (43.06%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.62% | ||
| ROE | N/A | ||
| ROIC | 50.62% |
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
1.3 Margins
- Looking at the Profit Margin, with a value of 10.34%, INDV belongs to the top of the industry, outperforming 84.90% of the companies in the same industry.
- INDV's Profit Margin has declined in the last couple of years.
- The Operating Margin of INDV (24.49%) is better than 92.19% of its industry peers.
- In the last couple of years the Operating Margin of INDV has remained more or less at the same level.
- INDV has a Gross Margin of 85.51%. This is amongst the best in the industry. INDV outperforms 88.54% of its industry peers.
- In the last couple of years the Gross Margin of INDV has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.49% | ||
| PM (TTM) | 10.34% | ||
| GM | 85.51% |
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
2. INDV Health Analysis
2.1 Basic Checks
- INDV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- There is no outstanding debt for INDV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- INDV has an Altman-Z score of 2.54. This is not the best score and indicates that INDV is in the grey zone with still only limited risk for bankruptcy at the moment.
- INDV has a better Altman-Z score (2.54) than 66.67% of its industry peers.
- The Debt to FCF ratio of INDV is 2.68, which is a good value as it means it would take INDV, 2.68 years of fcf income to pay off all of its debts.
- With an excellent Debt to FCF ratio value of 2.68, INDV belongs to the best of the industry, outperforming 92.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 2.68 | ||
| Altman-Z | 2.54 |
ROIC/WACC5.32
WACC9.51%
2.3 Liquidity
- INDV has a Current Ratio of 0.96. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
- INDV has a worse Current ratio (0.96) than 85.42% of its industry peers.
- A Quick Ratio of 0.79 indicates that INDV may have some problems paying its short term obligations.
- INDV has a worse Quick ratio (0.79) than 82.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.96 | ||
| Quick Ratio | 0.79 |
3. INDV Growth Analysis
3.1 Past
- INDV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 459.09%, which is quite impressive.
EPS 1Y (TTM)459.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.13%
3.2 Future
- The Earnings Per Share is expected to decrease by -3.07% on average over the next years.
- Based on estimates for the next years, INDV will show a small growth in Revenue. The Revenue will grow by 0.79% on average per year.
EPS Next Y25.28%
EPS Next 2Y17.02%
EPS Next 3Y13.27%
EPS Next 5Y-3.07%
Revenue Next Year-2.63%
Revenue Next 2Y1.23%
Revenue Next 3Y3.01%
Revenue Next 5Y0.79%
3.3 Evolution
4. INDV Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 12.37, the valuation of INDV can be described as correct.
- Based on the Price/Earnings ratio, INDV is valued cheaply inside the industry as 87.50% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 26.17. INDV is valued rather cheaply when compared to this.
- INDV is valuated reasonably with a Price/Forward Earnings ratio of 9.87.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of INDV indicates a rather cheap valuation: INDV is cheaper than 88.02% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 23.05, INDV is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.37 | ||
| Fwd PE | 9.87 |
4.2 Price Multiples
- 84.90% of the companies in the same industry are more expensive than INDV, based on the Enterprise Value to EBITDA ratio.
- INDV's Price/Free Cash Flow ratio is rather cheap when compared to the industry. INDV is cheaper than 81.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.71 | ||
| EV/EBITDA | 11.71 |
4.3 Compensation for Growth
- INDV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of INDV may justify a higher PE ratio.
- A more expensive valuation may be justified as INDV's earnings are expected to grow with 13.27% in the coming years.
PEG (NY)0.49
PEG (5Y)N/A
EPS Next 2Y17.02%
EPS Next 3Y13.27%
5. INDV Dividend Analysis
5.1 Amount
- INDV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
INDV Fundamentals: All Metrics, Ratios and Statistics
30.42
-0.05 (-0.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26 2026-02-26/bmo
Earnings (Next)04-23 2026-04-23
Inst Owners86.43%
Inst Owner Change0%
Ins Owners3.62%
Ins Owner Change39.75%
Market Cap3.80B
Revenue(TTM)N/A
Net Income(TTM)122.00M
Analysts84.62
Price Target47.79 (57.1%)
Short Float %10.15%
Short Ratio4.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)81.89%
Min EPS beat(2)71.47%
Max EPS beat(2)92.31%
EPS beat(4)4
Avg EPS beat(4)70.49%
Min EPS beat(4)45.92%
Max EPS beat(4)92.31%
EPS beat(8)6
Avg EPS beat(8)12.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.31%
Min Revenue beat(2)17.53%
Max Revenue beat(2)21.1%
Revenue beat(4)4
Avg Revenue beat(4)14.97%
Min Revenue beat(4)8.6%
Max Revenue beat(4)21.1%
Revenue beat(8)5
Avg Revenue beat(8)7.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.82%
PT rev (3m)23.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)1.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.37 | ||
| Fwd PE | 9.87 | ||
| P/S | 3.22 | ||
| P/FCF | 31.71 | ||
| P/OCF | 21.14 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.71 |
EPS(TTM)2.46
EY8.09%
EPS(NY)3.08
Fwd EY10.13%
FCF(TTM)0.96
FCFY3.15%
OCF(TTM)1.44
OCFY4.73%
SpS9.43
BVpS-1.66
TBVpS-1.67
PEG (NY)0.49
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.62% | ||
| ROE | N/A | ||
| ROCE | 64.08% | ||
| ROIC | 50.62% | ||
| ROICexc | 3805.17% | ||
| ROICexgc | 5707.75% | ||
| OM | 24.49% | ||
| PM (TTM) | 10.34% | ||
| GM | 85.51% | ||
| FCFM | 10.17% |
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)54.5%
ROCE(5y)38.6%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
F-Score8
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 2.68 | ||
| Debt/EBITDA | 0.97 | ||
| Cap/Depr | 230.77% | ||
| Cap/Sales | 5.08% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 57.14% | ||
| Profit Quality | 98.36% | ||
| Current Ratio | 0.96 | ||
| Quick Ratio | 0.79 | ||
| Altman-Z | 2.54 |
F-Score8
WACC9.51%
ROIC/WACC5.32
Cap/Depr(3y)163.83%
Cap/Depr(5y)132.28%
Cap/Sales(3y)2.67%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)459.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.25%
EPS Next Y25.28%
EPS Next 2Y17.02%
EPS Next 3Y13.27%
EPS Next 5Y-3.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.13%
Revenue Next Year-2.63%
Revenue Next 2Y1.23%
Revenue Next 3Y3.01%
Revenue Next 5Y0.79%
EBIT growth 1Y8.24%
EBIT growth 3Y11.69%
EBIT growth 5Y7.28%
EBIT Next Year1051.87%
EBIT Next 3Y148.64%
EBIT Next 5Y64.69%
FCF growth 1Y236.36%
FCF growth 3Y-74.97%
FCF growth 5Y-48.94%
OCF growth 1Y446.15%
OCF growth 3Y-53.28%
OCF growth 5Y-24.93%
INDIVIOR PHARMACEUTICALS INC / INDV Fundamental Analysis FAQ
What is the fundamental rating for INDV stock?
ChartMill assigns a fundamental rating of 5 / 10 to INDV.
What is the valuation status for INDV stock?
ChartMill assigns a valuation rating of 8 / 10 to INDIVIOR PHARMACEUTICALS INC (INDV). This can be considered as Undervalued.
How profitable is INDIVIOR PHARMACEUTICALS INC (INDV) stock?
INDIVIOR PHARMACEUTICALS INC (INDV) has a profitability rating of 7 / 10.
Can you provide the financial health for INDV stock?
The financial health rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 4 / 10.
What is the expected EPS growth for INDIVIOR PHARMACEUTICALS INC (INDV) stock?
The Earnings per Share (EPS) of INDIVIOR PHARMACEUTICALS INC (INDV) is expected to grow by 25.28% in the next year.